TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07612137: A Phase Ib/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBI3005 Combination Therapy in Participants With Advanced Solid Tumors

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 282 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07612137 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07612137 Rescue Dossier →